Longboard pharmaceuticals to participate in cantor fitzgerald's virtual rare orphan disease summit

San diego, march 23, 2022 (globe newswire) -- longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate virtually in the rare and general epilepsy and seizure disorders panel during cantor fitzgerald's rare orphan disease summit, taking place march 29–30, 2022.
LBPH Ratings Summary
LBPH Quant Ranking